1. Home
  2. MPLX vs NTRA Comparison

MPLX vs NTRA Comparison

Compare MPLX & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MPLX LP

MPLX

MPLX LP

SELL

Current Price

$57.42

Market Cap

55.9B

Sector

Energy

ML Signal

SELL

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$287.44

Market Cap

56.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPLX
NTRA
Founded
2012
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical Specialities
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.9B
56.7B
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
MPLX
NTRA
Price
$57.42
$287.44
Analyst Decision
Buy
Strong Buy
Analyst Count
15
22
Target Price
$62.31
★ $410.26
AVG Volume (30 Days)
1.7M
★ 1.9M
Earning Date
11-03-2026
11-05-2026
Dividend Yield
★ 8.46%
N/A
EPS Growth
N/A
★ 0.65
EPS
★ N/A
N/A
Revenue
★ $12,998,000,000.00
$210,939,000.00
Revenue This Year
$14.30
$30.65
Revenue Next Year
$6.79
$21.31
P/E Ratio
$11.76
★ N/A
Revenue Growth
★ 8.92
N/A
52 Week Low
$51.60
$181.00
52 Week High
$60.95
$437.41

Technical Indicators

Market Signals
Indicator
MPLX
NTRA
Relative Strength Index (RSI) 48.46 26.33
Support Level $56.89 $189.54
Resistance Level $57.45 $288.04
Average True Range (ATR) 1.16 21.43
MACD -0.04 -10.31
Stochastic Oscillator 40.47 5.81

Price Performance

Historical Comparison
MPLX
NTRA

About MPLX MPLX LP

MPLX is a partnership that owns pipelines and gathering and processing assets with extensive holdings in the Appalachian and Permian regions. The asset base is made up of crude oil and refined products assets dropped down from Marathon Petroleum, its sponsor, and natural gas and natural gas liquids gathering and processing assets that were purchased or built.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: